Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
for
Migraine
Location: Nashua NH, Stamford CT, Morristown NJ, Philadelphia PA,
Sponsor: AbbVie
Sex: All
Age: 6 - 17
Code: NCT05125302
Phase3, Recruiting
Featured
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
for
Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer
Location: New York NY, Philadelphia PA, Nashville TN, Chicago IL,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT06858813
Phase1, Recruiting
Featured
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Location: Burlington MA, East Greenwich RI, Carmel NY,
Sponsor: 89bio, Inc.
Sex: All
Age: 18 - 70+
Code: NCT06318169
Phase3, Recruiting
Featured
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
for
Episodic Migraine
Location: Morristown NJ, Philadelphia PA, Franklin VA, Miami FL,
Sponsor: AbbVie
Sex: All
Age: 6 - 17
Code: NCT05711394
Phase3, Recruiting
Featured
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Location: Burlington MA, East Greenwich RI, Framingham MA,
Sponsor: 89bio, Inc.
Sex: All
Age: 18 - 70+
Code: NCT06419374
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Featured
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.